WALL COLMONOY LIMITED
Company number 00788765 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Of course. Here is the financial health assessment for Wall Colmonoy Limited, based on the data provided.
Wall Colmonoy Limited - Financial Health Assessment
Patient: Wall Colmonoy Limited Date of Examination: Financial Year Ending 31 December 2024 Examining Physician: Financial Wellness Specialist
1. Financial Health Score: B (Good)
Explanation: The company presents a "Good" financial health score. It is a stable, going concern with a robust business model and strong operational performance (EBITDA). However, the financial statements filed at Companies House show a "shell" structure (minimal assets and liabilities) that is inconsistent with the narrative of a £36M turnover business. This creates a significant diagnostic discrepancy. The underlying business appears healthy, but the public record is misleading and prevents a standard ratio-based analysis. The diagnosis is based heavily on the strategic report's narrative rather than the balance sheet.
2. Key Vital Signs & Symptoms Analysis
There is a fundamental disconnect between the company's public filings and its own strategic report. We will analyze both.
Vital Signs from Public Filings (Balance Sheet)
These are the metrics from the "Annual Report and Financial Statements" as filed at Companies House. They show a very small, stable entity.
| Metric | 2024 | 2023 | 2022 | Trend | Interpretation |
|---|---|---|---|---|---|
| Total Assets | £17,896 | £17,685 | £18,033 | Stable | Symptom of a Dormant Shell? This is an extremely low asset base. It suggests the company itself holds very few assets directly. |
| Net Assets | £17,012 | £16,130 | £17,004 | Stable | Healthy Vital Sign (for a shell). Shareholders' funds are positive and stable, indicating no insolvency at this level. |
| Cash at Bank | £784 | £488 | £1,042 | Low | Symptom of Thin Liquidity. The company has virtually no cash reserves in its own name. This is not typical for a company with £36M in sales. |
| Turnover | N/A | N/A | £34,877 | N/A | Symptom of Inconsistency. The filed accounts show turnover at a fraction of the £36M reported in the strategic report. |
Vital Signs from Strategic Report (Operational Performance)
These metrics are from the company's own narrative and are the true indicators of business health.
| Metric | 2024 | 2023 | Trend | Interpretation |
|---|---|---|---|---|
| Turnover | £36.3M | £41.5M | -13% | Symptom of Commodity Price Sensitivity. The drop is attributed to lower nickel and cobalt prices, not a loss of volume. This is a manageable risk. |
| EBITDA | £1.7M | £1.2M | +38% | Strong Vital Sign. This is the most important indicator. It shows the core business is significantly more profitable, driven by new products and market expansion. |
| EBITDA Margin | ~4.6% | ~2.9% | Improving | Symptom of Recovery. The margin is still low for a manufacturer but shows a strong positive trajectory. |
| Employees | ~36 (implied) | ~42 (implied) | Stable | Healthy Vital Sign. Indicates a stable, operating workforce. |
3. Diagnosis: The "Shell & Substance" Condition
Primary Diagnosis: Dual-Entity Accounting Structure. The company appears to be a holding entity that owns the intellectual property and brand, while the operational business (manufacturing, sales, employees) is likely managed and held elsewhere within a corporate group. The £17k of net assets represents the bare shell of the company. The £36M turnover, £1.7M EBITDA, and 36+ employees are the "substance" of the business, which is not reflected on this balance sheet.
Secondary Diagnosis: Operational Turnaround (Positive). The underlying business has successfully navigated a period of commodity price volatility. Despite a 13% drop in revenue, it has improved profitability by 38%. This is a sign of excellent management and a robust business model. The company is not in distress; it is in a phase of growth and operational efficiency.
Symptoms of Distress (from public filings): The low cash balance (£784) and minimal asset base are classic symptoms of a "zombie company" or a company in decline. However, this is a false positive caused by the accounting structure.
Symptoms of Health (from strategic report): The strong EBITDA growth, investment in new capabilities, expansion into new markets, and stable workforce are the vital signs of a healthy, growing business.
4. Recommendations: Actions to Improve Financial Wellness
The recommendations are split to address both the accounting structure and the underlying business.
For the Accounting Structure (Transparency): 1. Prescribe a Clearer Picture: The company should file accounts that clearly show the relationship between the "shell" entity and the operational business. A note to the accounts explaining the group structure and where the operating assets, liabilities, and cash are held would be invaluable for creditors, investors, and analysts. This is a "band-aid" for a confusing public record. 2. Monitor Inter-Company Balances: Ensure that the debtors and creditors between the shell entity and the operating entity are well-documented and reconciled. A large, unexplained inter-company balance could be a "silent killer" if not managed properly.
For the Underlying Business (Operational Health): 3. Strengthen the EBITDA Margin: While the 38% increase is excellent, a ~4.6% margin is still fragile. The company should continue its focus on high-margin new products and operational efficiency (Lean practices) to push this margin towards 8-10%. This is the "exercise and diet" plan for the business. 4. Build a Cash Reserve: The company's own narrative says it "maintains excellent relations with Natwest Bank." While a good safety net, the business should aim to build its own cash reserves to reduce reliance on borrowing and provide a buffer against future commodity price shocks. This is the "emergency fund" for the company. 5. Manage Commodity Risk: The company acknowledges foreign exchange and supply chain risks. The use of hedging contracts is prudent. This practice should be formalized into a documented policy to ensure it remains a risk-management tool, not a speculative activity.
Prognosis
Excellent. The underlying business is demonstrating strong operational health and a clear strategy for profitable growth. The "shell & substance" accounting structure creates a misleading public record, but does not threaten the company's viability. The key risk is a significant downturn in its key markets (aerospace, defence, oil & gas) or a failure to manage its commodity price exposure. As long as the company continues its disciplined approach to sales, operations, and innovation, its financial wellness will remain strong.